This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repligen Reports First Quarter 2013 Financial Results

- Total Revenue and Bioprocessing Revenue Grow 28% Over First Quarter 2012 - - Net Income Increases 91% to $2.3 million – - Earnings Conference Call and Webcast Today at 9:00 a.m. EDT -

WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today reported financial results for the first quarter ended March 31, 2013. Below are financial and business highlights for the first quarter of 2013, financial guidance for the year and access information for today's discussion.

Financial Highlights:
  • Bioprocessing product revenue for the first quarter of 2013 was $11.9 million, a 28% increase over the first quarter of 2012.  
  • Total revenue for the first quarter of 2013 was $16.5 million, a 28% increase over the first quarter of 2012.  
  • Net income increased to $2.3 million for the first quarter of 2013 compared to $1.2 million for the first quarter of 2012; earnings per diluted share were $0.07 for the first quarter of 2013 compared to $0.04 for the first quarter of 2012.  
  • Cash and investments as of March 31, 2013 totaled $54.1 million compared to $50.0 million as of December 31, 2012.

Operating expenses for the three-month period ended March 31, 2013 were $12.9 million compared to $11.7 million for the same period in 2012, an increase of $1.3 million or 11%. These operating expenses included an increase in cost of product revenue due to higher product sales, partially offset by decreases in both research and development expenses and selling, general and administrative expenses. For the first quarter of 2013 compared to the same period in 2012, research and development (R&D) expense decreased by $625,000, or 22%, primarily due to lower spending on our clinical development programs as a result of our strategic decision to focus on building our core bioprocessing business. This is the Company's first financial reporting period for which both the current and preceding year's periods reflect combined financial results since the Company's acquisition of Novozymes Biopharma AB (now Repligen Sweden AB) in December 2011.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.27 1.70%
FB $117.58 -0.83%
GOOG $695.47 -0.39%
TSLA $234.32 -3.10%
YHOO $36.18 -0.94%


Chart of I:DJI
DOW 17,767.03 -124.13 -0.69%
S&P 500 2,064.74 -16.69 -0.80%
NASDAQ 4,776.10 -41.4940 -0.86%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs